Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell, Inc. director William W. Burke received an equity award in the form of restricted stock units. On the reported date, he acquired 7,838 shares of common stock at no cash cost through this grant, bringing his directly held position to 25,229 shares after the transaction.
Taylor Joseph Michael reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. director Joseph Michael Taylor received a grant of 7,838 shares of common stock in the form of restricted stock units (RSUs). The award was recorded at a price of $0.00 per share, reflecting a compensation grant rather than an open-market purchase or sale.
Following this RSU award, Taylor directly holds 67,073 shares of Ceribell common stock. This filing reports a routine equity-based compensation grant and does not reflect any discretionary buying or selling of shares on the market.
ROBERTSON REBECCA B reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. director Rebecca B. Robertson received a grant of 7,838 restricted stock units on June 2, 2026. These RSUs were awarded at no cash cost per unit as equity compensation rather than an open-market purchase. After this award, she holds 26,587 common shares and RSUs directly.
CeriBell, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 2, 2026. Stockholders elected two Class II directors, Josef Parvizi, M.D., Ph.D., and Rebecca Robertson, to serve until the 2029 annual meeting and until successors are elected.
Parvizi received 25,961,193 votes for and 2,311,420 withheld, while Robertson received 25,948,634 votes for and 2,323,979 withheld; each had 4,374,728 broker non-votes. Stockholders also approved ratifying PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2026 with 32,623,328 votes for, 5,177 against, and 18,836 abstentions.
Ceribell, Inc. Chief Revenue Officer Joseph S. Manni reported routine equity compensation activity and a small share sale. He sold 1,378 shares of Common Stock at $18.00 per share on May 21, 2026 to cover tax withholding obligations from vesting restricted stock units, and still holds 56,291 shares afterward.
Separately, he received a performance-based stock option covering 3,500 shares of Common Stock at an exercise price of $9.41 per share, tied to 2025 performance metrics. This option is fully vested as of March 15, 2026 and is currently exercisable, with an expiration date in 2034.
Ceribell, Inc. senior vice president David Foehr reported small open‑market sales of company stock that were tied to taxes on equity compensation. He sold 987 shares of common stock on May 21 at $18.00 per share and 862 shares on May 22 at $18.80 per share, totaling 1,849 shares. According to the disclosure, these shares were sold to cover tax withholding obligations from the vesting of restricted stock units and were executed under a pre‑arranged Rule 10b5‑1 trading plan. After these transactions, Foehr directly holds 37,751 shares of Ceribell common stock.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported a small sale of 1,966 shares of Common Stock at $18.00 per share. According to the footnote, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. After this transaction, Woo directly owns 195,682 shares, so the sale represents only a minor portion of his overall holdings and appears to be a routine tax-related event rather than a large discretionary trade.
Ceribell, Inc. Chief Financial Officer Scott Blumberg reported a small share sale tied to compensation. He sold 1,387 shares of common stock at $18.00 per share to cover tax withholding obligations arising from the vesting of restricted stock units. After this transaction, he continues to hold 147,683 shares of Ceribell common stock directly, indicating this was a routine, tax-related disposition rather than a large reduction of his overall position.
Ceribell, Inc. President and CEO Chao Xingjuan reported a small share sale mainly for tax purposes. On the Form 4 date, she sold 6,030 shares of common stock at $18.00 per share to cover tax withholding obligations tied to vesting restricted stock units. After this transaction, she directly holds 830,317 shares and may be deemed to beneficially own 369,088 additional shares indirectly through the ACP 2021 Trust.
CBLL filed Rule 144 notices reporting sales of Common Stock by an affiliate.
The filing lists completed sales by David J. Foehr on 02/23/2026 (569 shares, $11,263.07), 02/24/2026 (781 shares, $15,604.38), 03/03/2026 (4,560 shares, $81,168.00), and 05/21/2026 (987 shares, $17,761.95). The filing also records 862 shares associated with restricted stock vesting on 05/20/2026 tied to compensation.